Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Wang, M. (Michael); Rule, S. (Simon); Zinzani, P.L. (P. L.); Goy, A. (Andre); Casasnovas, R. O. (René Olivier); Smith, S.D. (Stephen D.); Damaj, G. (Gandhi); Doorduijn, J.K. (Jeanette K.); Lamy, T. (Thierry); Morschhauser, F. (Franck); Panizo, C. (Carlos); Shah, B. (Bijal); Davies, A. (Andrew); Eek, R. (Richard); Dupuis, J. (Jehan); Jacobsen, E. (Eric); Kate, A.P. (Arnon P.); Le-Gouill, S. (Steven); Oberic, L. (Lucie); Robak, T. (Tadeusz); Jain, P. (Preetesh); Frigault, M.M. (Melanie M.); Raquel; Nguyen, D. (Dorothy); Patel, P (Priti); Yin, M. (Ming); Dlugosz-Danecka, M. (Monika)

Palabras clave :

Bruton tyrosine kinase (BTK)
Mantle cell lymphoma (MCL)
Acalabrutinib
Clinical data

Fecha de publicación :

2019

Editorial :

Springer Science and Business Media LLC

ISSN :

0887-6924

Nota:

This article is licensed under a Creative Commons Attribution 4.0 International License

Cita:

Wang, M. (Michael); Rule, S. (Simon); Zinzani, P.L. (P.L.); et al. "Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma". Leukemia. 33, 2019, 2762 - 2766

Resumen

Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6 ) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018.

URI :

https://hdl.handle.net/10171/62620

DOI:

10.1038/s41375-019-0575-9

Aparece en las colecciones:

DA - CUN - Hematología y Hemoterapia - Artículos de revista

Ficheros en este ítem: